849475-89-4 Usage
General Description
5,6-Dihydroxy-2-pyridin-2-yl-pyrimidine-4-carboxylic acid methyl ester is a chemical compound with the molecular formula C11H10N4O4. It is a methyl ester derivative of pyridine-2,4-dicarboxylic acid and pyrimidin-2,4,6-triol. 5,6-DIHYDROXY-2-PYRIDIN-2-YL-PYRIMIDINE-4-CARBOXYLIC ACID METHYL ESTER has potential applications in pharmaceutical and agrochemical industries due to its versatile chemical structure and potential biological activities. It is used in the synthesis of various pharmaceutical drugs and as a building block in the production of agrochemical compounds. The structure of 5,6-dihydroxy-2-pyridin-2-yl-pyrimidine-4-carboxylic acid methyl ester makes it a valuable intermediate for the development and production of various bioactive compounds.
Check Digit Verification of cas no
The CAS Registry Mumber 849475-89-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,4,9,4,7 and 5 respectively; the second part has 2 digits, 8 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 849475-89:
(8*8)+(7*4)+(6*9)+(5*4)+(4*7)+(3*5)+(2*8)+(1*9)=234
234 % 10 = 4
So 849475-89-4 is a valid CAS Registry Number.
849475-89-4Relevant articles and documents
COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND F1BROTIC DISEASE
-
Paragraph 00541, (2020/07/14)
Provided herein are methods and compositions for treating cancers, inflammatory diseases, rasopathies, and fibrotic disease involving aberrant Ras superfamily signaling through the binding of compounds to the GTP binding domain of Ras superfamily proteins including, in certain cases, K-Ras and mutants thereof, and a method for assaying such compositions.
HIV-1 NUCLEOCAPSID INHIBITORS
-
, (2018/04/21)
The present invention discloses novel anti-HIV agents targeting the HIV Nucleocapsid protein (NC), which is one of the most conserved sequences within HIV strains and is highly required for HIV replication. The compounds of the invention are particularly useful to overcome antiretroviral drug-resistance in HIV-1 infected individuals.
